Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of TNM002 in healthy subjects
NCT04629131Phase 1Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Atorva in Tetanus (4 cohorts), sponsored by Trinomab Pharmaceutical. Primary endpoints: Incidence and severity of adverse events up to 105 days, Clinically significant abnormality in physical examinations up to 105 days and 6 more. Started Nov 2020; status: completed.
02
Drugs
Atorva
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT04629131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629131.